HomeSOBI • STO
add
Swedish Orphan Biovitrum AB (publ)
Previous close
kr 280.00
Day range
kr 279.00 - kr 286.20
Year range
kr 189.03 - kr 302.00
Market cap
99.93B SEK
Avg Volume
434.07K
P/E ratio
45.56
Dividend yield
-
Primary exchange
STO
Market news
.DJI
0.46%
Financials
Income Statement
Revenue
Net income
(SEK) | Mar 2024info | Y/Y change |
---|---|---|
Revenue | 6.26B | 19.41% |
Operating expense | 3.27B | 21.99% |
Net income | 800.00M | -25.02% |
Net profit margin | 12.79 | -37.21% |
Earnings per share | 2.67 | -25.00% |
EBITDA | 2.38B | 10.15% |
Effective tax rate | 18.53% | — |
Balance Sheet
Total assets
Total liabilities
(SEK) | Mar 2024info | Y/Y change |
---|---|---|
Cash and short-term investments | 527.00M | 166.16% |
Total assets | 74.52B | 38.22% |
Total liabilities | 38.62B | 48.05% |
Total equity | 35.90B | — |
Shares outstanding | 339.87M | — |
Price to book | 2.65 | — |
Return on assets | 4.94% | — |
Return on capital | 6.70% | — |
Cash Flow
Net change in cash
(SEK) | Mar 2024info | Y/Y change |
---|---|---|
Net income | 800.00M | -25.02% |
Cash from operations | 2.26B | 13.77% |
Cash from investing | -745.00M | 77.13% |
Cash from financing | -1.86B | -1,251.23% |
Net change in cash | -378.00M | 67.50% |
Free cash flow | 387.62M | 116.86% |
About
Swedish Orphan Biovitrum AB is an international biopharmaceutical company dedicated to treatments in the areas of haematology, immunology and specialty care, based in Stockholm, Sweden.
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees. Wikipedia
Founded
1939
Website
Employees
1,752